US-based cell therapy company Arsenal Biosciences, Inc. has announced that Bristol-Myers Squibb (BMS, NYSE: BMY) has exercised its exclusive license option for the AB-4000 series. This program originated from a multi-year agreement between the two companies, which was initially established in December 2020, aimed at advancing next-generation T cell therapies for the treatment of solid tumors.
Agreement Details and Collaboration
Under the terms of the agreement, ArsenalBio is responsible for discovering and developing preclinical candidates against multiple targets. Bristol-Myers Squibb (BMS) retains the option to obtain an exclusive worldwide license to further develop and commercialize these preclinical candidates. Following the exercise of this option, BMS will assume sole responsibility for the development and commercialization of the licensed candidates.
Expansion of Strategic Collaboration
In January 2022, BMS exercised an option to initiate a new program, further expanding its strategic collaboration with ArsenalBio. This was followed by a limited co-exclusive commercial license agreement in July 2023, which granted BMS the use of ArsenalBio’s proprietary TME control technology. This technology is intended to potentially enhance the therapeutic effects of CAR-T therapies in a limited number of BMS’s cell therapy products.
AB-4000 Series: Innovation in Solid Tumor Treatment
The AB-4000 series, developed using ArsenalBio’s proprietary synthetic biology toolkit, is specifically designed to treat solid tumors. This innovative approach represents a significant step forward in the development of cell therapies, leveraging advanced synthetic biology techniques to improve treatment outcomes for patients with solid tumors.-Fineline Info & Tech
